John Tamerius Sells 8,878 Shares of Quidel Corp. (QDEL) Stock
Quidel Corp. (NASDAQ:QDEL) SVP John Tamerius sold 8,878 shares of the company’s stock in a transaction on Friday, November 25th. The shares were sold at an average price of $23.50, for a total value of $208,633.00. Following the completion of the transaction, the senior vice president now directly owns 32,418 shares in the company, valued at approximately $761,823. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Quidel Corp. (NASDAQ:QDEL) opened at 22.93 on Thursday. The stock’s market capitalization is $748.50 million. Quidel Corp. has a 12-month low of $13.21 and a 12-month high of $23.94. The stock’s 50 day moving average is $21.20 and its 200 day moving average is $20.26.
Quidel Corp. (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, October 26th. The company reported $0.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.12. Quidel Corp. had a negative net margin of 6.40% and a negative return on equity of 0.81%. The business had revenue of $49.30 million for the quarter, compared to analysts’ expectations of $50.88 million. During the same period in the prior year, the firm earned ($0.05) earnings per share. Quidel Corp.’s revenue was up 5.3% compared to the same quarter last year. Analysts forecast that Quidel Corp. will post ($0.16) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “John Tamerius Sells 8,878 Shares of Quidel Corp. (QDEL) Stock” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2016/12/01/john-tamerius-sells-8878-shares-of-quidel-corp-qdel-stock.html.
A number of institutional investors have recently made changes to their positions in the stock. Macquarie Group Ltd. raised its position in shares of Quidel Corp. by 27.7% in the second quarter. Macquarie Group Ltd. now owns 858,387 shares of the company’s stock valued at $15,331,000 after buying an additional 186,020 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Quidel Corp. during the third quarter valued at $1,767,000. Baird Financial Group Inc. raised its position in shares of Quidel Corp. by 34.2% in the second quarter. Baird Financial Group Inc. now owns 300,847 shares of the company’s stock valued at $5,373,000 after buying an additional 76,639 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Quidel Corp. by 7.2% in the third quarter. BlackRock Fund Advisors now owns 685,761 shares of the company’s stock valued at $15,148,000 after buying an additional 46,271 shares in the last quarter. Finally, Societe Generale acquired a new position in shares of Quidel Corp. during the second quarter valued at $616,000. Institutional investors and hedge funds own 92.28% of the company’s stock.
Several equities analysts have weighed in on the stock. Canaccord Genuity set a $22.00 price objective on shares of Quidel Corp. and gave the stock a “hold” rating in a research report on Thursday, October 27th. Zacks Investment Research upgraded shares of Quidel Corp. from a “sell” rating to a “hold” rating in a research report on Friday, November 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $21.58.
About Quidel Corp.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers.
Receive News & Stock Ratings for Quidel Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corp. and related stocks with our FREE daily email newsletter.